Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb, randomized, double-blind, placebo-controlled clinical trial of avacopan for the treatment of Hidradenitis Suppurativa

Trial Profile

A Phase IIb, randomized, double-blind, placebo-controlled clinical trial of avacopan for the treatment of Hidradenitis Suppurativa

Planning
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2018

At a glance

  • Drugs Avacopan (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Nov 2018 New trial record
    • 08 Nov 2018 According to a ChemoCentryx media release, the company has submitted the Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the Phase IIb clinical development of avacopan in Hidradenitis Suppurativa. The trial is expected to be initiated by the end of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top